Effects of DPP4 inhibitor and long-acting insulin therapy on blood biochemical indexes of type 2 diabetes: a comparative study
-
摘要:
目的 比较二肽基肽酶4(DPP4)抑制剂与长效胰岛素治疗2型糖尿病患者时相关血生化指标影响。 方法 对我院2017年1月~2018年7月期间收治的40例2型糖尿病患者,根据治疗方法的不同分为DPP4抑制剂组(沙格列汀)与长效胰岛素组(地特胰岛素或甘精胰岛素),经过3月治疗后,检测每例患者静脉血中血糖、胰岛素水平及胰岛素抵抗系数、血脂情况。 结果 DPP4组和长效胰岛素组患者的血糖均得到良好控制,两组控制程度差异无统计学意义(F=1.296,P>0.05),而DPP4抑制剂很好的改善了胰岛素的敏感性,DPP4组的胰岛素抵抗系数较长效胰岛素组明显更低,差异具有统计学意义(t=8.11,P<0.05)。DPP4抑制剂相比较长效胰岛素,DPP4抑制剂在甘油三酯、高密度脂蛋白胆固醇的调控上具有优势,甘油三酯的水平更低而高密度脂蛋白胆固醇的水平更高(P<0.05),但在总胆固醇、极低密度脂蛋白胆固醇、低密度脂蛋白胆固醇的水平调节上差异无统计学意义(P>0.05)。 结论 DPP4抑制剂作为新型2型糖尿病的治疗药物,相比较长效胰岛素能够很好的控制患者的血糖水平,并且增加患者对胰岛素的敏感性,同时也能更好地调节患者的血脂水平。 Abstract:Objective To investigate the effects of DPP4 inhibitor and long-acting insulin therapy on blood biochemical indexes of type 2 diabetes. Methods 440 cases of type 2 diabetes patients in our department from January 2017 to July 2018 were included and divided into DPP4 group (Saxagliptin) and long-acting insulin group (insulin glargine). All patients received corresponding drugs for 3 months, after which the serum blood glucose, blood lipid, blood insulin and insulin resistance index of each group were detected and recorded. Result Blood glucose was well controlled in both groups, and there was no significance between the control degrees(F=1.296, P=0.578). However, the insulin resistance index of the DPP4 group was significant lower than that of the long-acting insulin group (t=8.11, P<0.05). Compare to long-acting insulin, DPP4 inhibitor improve insulin sensitivity. The level of triglyceride (TG) of DPP4 group was significantly higher than that of the long-acting insulin group, while the level of highly density lipoprotein cholesterol (HDLC) of DPP4 group was significantly lower than that of its counterpart (P<0.05). indicating that DPP4 inhibitor is better at regulating the level of TG and HDLC. There was no significant difference in the level of total cholesterol (TC), very low density lipoprotein cholesterol (vLDL-C) and low density lipoprotein cholesterol (LDLC) between two groups(P>0.05). Conclusion DPP4 inhibitor, as a new drug used for type 2 diabetes, can effectively regulate the blood glucose and blood lipid and increase the insulin sensibility. -
Key words:
- DPP4 inhibitors /
- long-acting insulin /
- type 2 diabetes
-
表 1 DPP4抑制剂组与长效胰岛素组治疗后患者血糖和胰岛素水平的比较(Mean±SD)
组别空腹血糖(mmol/L) 总胆固醇(mU/L) 胰岛素抵抗系数 DPP4抑制剂组 6.96±0.15 1.28±0.05 0.40±0.01 长效胰岛素组 8.62±0.17 3.15±0.07 1.21±0.04 F 1.296 3.254 8.110 P 0.578 <0.0001 <0.0001 表 2 DPP4抑制剂组与长效胰岛素组治疗后患者血脂水平的比较(Mean±SD)
组别甘油三酯 总胆固醇 极低密度脂蛋白胆固醇 低密度脂蛋白胆固醇 高密度脂蛋白胆固醇 DPP4抑制剂组 1.50±0.05 3.61±0.17 0.67±0.03 2.11±0.08 1.54±0.06 长效胰岛素组 2.24±0.09 3.99±0.13 0.73±0.03 2.31±0.07 1.27±0.05 F 2.906 1.544 1.058 1.470 1.314 P <0.001 0.082 0.215 0.066 0.002 -
[1] Mex O. A study of peripheral arterial disease in type2 diabetes mellitus[J]. J Assoc Physicians India, 2016, 64(1): 40-4. [2] Bashier MA. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial[J]. J Diabetes Metab Disord, 2015,14(5): 48-52. [3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J]. 中国糖尿病杂志, 2014, 22(8): 42-4. http://guide.medlive.cn/guideline/5332 [4] Staiger H, Staiger K, Boehm A, et al. DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity[J]. PLoS One, 2013, 62(1): A433-4. http://paperity.org/p/80384549/dpp4-gene-variation-affects-glp-1-secretion-insulin-secretion-and-glucose-tolerance-in [5] Xia C, Goud A, D'souza J, et al. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure[J]. Heart Fail Rev, 2017, 22(3): 299-304. doi: 10.1007/s10741-017-9617-4 [6] Chalichem NS, Gonugunta C, Krishnamurthy PT, et al. DPP4 inhibitors can be a drug of choice for type 3 diabetes: a mini review[J]. Am J Alzheimers Dis Other Demen, 2017, 32(7): 444-51. doi: 10.1177/1533317517722005 [7] Mousavi S. Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients[J]. Mol Biol Res Commun, 2017, 6(2): 91-4. [8] 谢宝强. 甘精胰岛素联合瑞格列奈治疗2型糖尿病临床疗效分析[J]. 现代预防医学, 2012, 39(21): 5786-9. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_xdyfyx201221117 [9] Bistola V. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors[J]. Heart Fail Rev ,2018,14(11):275-80. doi: 10.1007/s10741-018-9674-3 [10] Nargis T, Chakrabarti P. Significance of circulatory DPP4 activity in metabolic diseases[J]. IUBMB Life, 2018, 70(2): 112-9. doi: 10.1002/iub.v70.2 [11] Birnbaum Y. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes[J]. Cardiovasc Drugs Ther, 2018,23(7):127-33. doi: 10.1007/s10557-018-6778-x.pdf [12] 陶桂香, 徐 洋. 1型糖尿病发病机制及治疗研究[J]. 中国免疫学杂志, 2015,28(10): 1297-303. doi: 10.3969/j.issn.1000-484X.2015.10.001 [13] 陈 姬, 杨冯睿. 2型糖尿病合并视网膜病变老年患者血清脂联素及同型半胱氨酸的水平分析[J].重庆医学, 1994, 45(33): 51-2. [14] Alipour A, Zare H, Poursharifi H, et al. The intermediary role of Self-Efficacy in relation with stress, glycosylated haemoglobin and Health-Related quality of Life in patients with type2 diabetes[J]. Iran J Public Health, 2012, 41(12): 76-80. [15] Zhou BJ. The benefits and risks of DPP4-inhibitors vs sulfonylureas for patients with type 2 diabetes:accumulated evidence from randomised controlled trial[J].Int J Clin Pract, 2016, 70(2): 132-41. doi: 10.1111/ijcp.2016.70.issue-2 [16] 张 坤, 任巧华, 吴 韬, 等. 西格列汀联合二甲双胍治疗2型糖尿病合并代谢综合征的临床观察[J]. 中国药房, 2016, 27(17): 2364-6. doi: 10.6039/j.issn.1001-0408.2016.17.20 [17] Pirdehghan A, Poortalebi N. Predictors of adherence to type2 diabetes medication[J]. J Res Health Sci, 2016, 16(2): 72-5. http://europepmc.org/abstract/MED/27497773
点击查看大图
表(2)
计量
- 文章访问数: 1145
- HTML全文浏览量: 628
- PDF下载量: 3
- 被引次数: 0